Safety and Targeting of Anti-hk2 Antibody in mCRPC

Early Phase 1TerminatedNCT04116164

SpectronRX27 enrolled

Overview

This is an imaging trial, to develop h11B6 as a therapeutic radiopharmaceutical for men with mCRPC. This imaging study will be conducted to confirm the safety and estimate the mass amount of antibody h11B6, and confirm in vivo tumor targeting of the antibody, using Indium-111 (111In) radiolabeled h11B6 in subjects with advanced prostate cancer. This study will also provide the dosimetric information crucial for Phase 1 therapy.

It is the intent to develop h11B6 as a therapeutic radiopharmaceutical for men with mCRPC. This Phase 0 study will be conducted to confirm the safety, estimate the mass amount, and confirm in vivo tumor targeting of the antibody. This study will use Indium-111 (111In) radiolabeled h11B6 in subjects with mCRPC to image known sites of disease and identify a favorable mass amount of antibody for satisfactory tumor targeting with minimal/no accumulation off-target. In cohort 1, In-111 labeled h11B6 will remain fixed at 2 mg, and additional h11B6 will be added in 2 sub-cohorts (8 mg and 18 mg respectively); up to 6 patients may be entered into a sub-cohort. Additional patients (up to 6) will be studied once the most favorable mass and imaging time point have been established, to establish targeting of antibody to known disease. This study will provide the dosimetric information crucial for Phase 1 therapy.

Study Type

INTERVENTIONAL

Allocation

Purpose

OTHER

Masking

NONE

Enrollment

Conditions

Castration-Resistant Prostatic Cancer Metastatic Disease

Interventions

111In-DOTA-h11B6DRUG

4-6 mCi 111In labeled to 2 mg DOTA-h11B6; 0, 8 or 18 mg additional h11B6.

Eligibility

Sex: MALEMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Subjects with mCRPC will be eligible if they meet the following criteria: * Eastern Cooperative Oncology Group (ECOG) ≤ 1 * Histologically or cytologically confirmed adenocarcinoma of the prostate * Castrate levels of testosterone (\<50 ng/dL \[1.74 nmol/L\]) * Metastatic disease documented by imaging * Documented progressive mCRPC with androgen involvement as defined by - Prostate Cancer Working Group 3 * Acceptable laboratory parameters * At least 28 days since administration of any therapeutic radioactive isotope * Able to tolerate the conditions required to perform imaging studies (e.g., lying flat for at least 1 hour). Exclusion Criteria: * Known hypersensitivity to proteins, or other allergic diathesis that, in the opinion of the investigator, makes an immune response to humanized antibody likely * Radiotherapy or immunotherapy within 30 days, or single fraction of palliative radiotherapy within 14 days of administration of study agent * Any condition that, in the opinion of the Investigator, would impair the subject's ability to comply with study procedures and required study visits * Active, symptomatic, or untreated brain metastases.

Locations (1)

Memorial Sloan-Kettering Cancer Center

New York, New York, United States

Outcomes

Primary Outcomes

Serum pharmacokinetics

Serum clearance kinetics of 111In-DOTA-h11B6, only in cohort 1, at each mass amount of antibody (2, 10, and 20 mg).

Time frame: 6 months

Radioactivity Biodistribution

Radioactivity residence times in liver, kidneys and tumor, only in cohort 1, at each mass amount of antibody (2, 10, and 20 mg).

Time frame: 6 months

Radioactivity accumulation in known tumor sites

Number of known metastatic lesions in which there is increased uptake of 111In, in both cohorts 1 and 2.

Time frame: 9 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.